Component 1: Rapid Evaluation Program

The Rapid Evaluation Program was an attempt to get a first simple look at the major outcomes of treatment – quite simply, whether the patient is getting better, worse or staying the same.

The Rapid Evaluation Program was an optional extension of the Expanded Access Program (EAP) through the Mayo Clinic. As of August 23, 2020, The Mayo Clinic-led expanded access program has discontinued new physician and new patient enrollments. COVID-19 convalescent plasma remains available through emergency use authorization (EUA). On November 30, 2020, the FDA reissued the Letter of Authorization from August 23 to include a test acceptable for the manufacture of COVID-19 convalescent plasma. On February 4, 2021, the EUA was revised to limit use to high-titer COVID-19 convalescent plasma for the treatment of COVID-19. For more information about the EAP to EUA transition, please see the Mayo Clinic US COVID Plasma website

The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated with Convalescent Plasma